Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Svas Biosana SpAMIL:SVS 79 FCF Margin % is 2.70% as of Dec. 2025. GuruFocus rates MIL:SVS with a GF Score™ of 79/100 and a GF Value™ of €9.61 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Svas Biosana SpA ranks worse than 57.39% on this metric.
The historical rank and industry rank for Svas Biosana SpA's FCF Margin % or its related term are showing as below:
MIL:SVS'
s FCF Margin % Range Over the Past 10 Years
Min: -4.17 Med: -0.4 Max: 12.5
Current: -4.09
During the past 8 years, the highest FCF Margin % of Svas Biosana SpA was 12.50%. The lowest was -4.17%. And the median was -0.40%.
MIL:SVS's FCF Margin % is ranked worse than 57.39% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: -0.965
vs MIL:SVS: -4.09
The historical data trend for Svas Biosana SpA's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Svas Biosana SpA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Svas Biosana SpA FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Svas Biosana SpA's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Svas Biosana SpA's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Svas Biosana SpA (MIL:SVS) has a FCF Margin % of 2.70% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Svas Biosana SpA and its competitors. According to the industry distribution chart, Svas Biosana SpA ranks #466 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 57.4%.
Is Svas Biosana SpA's FCF Margin % too high?
Svas Biosana SpA's current FCF Margin % is 2.70%. Based on the distribution chart, Svas Biosana SpA ranks #466 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Svas Biosana SpA has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Svas Biosana SpA's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Svas Biosana SpA ranks #466 out of 812 companies for FCF Margin %. This places Svas Biosana SpA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Svas Biosana SpA and its competitors. Svas Biosana SpA's current FCF Margin % is 2.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Svas Biosana SpA stock overvalued right now?
Based on GuruFocus' analysis, Svas Biosana SpA (MIL:SVS) is currently considered Modestly Undervalued. The stock's GF Value™ is €9.61, compared to a current price of €8.38 — trading 12.8% below its estimated fair value. The current FCF Margin % is 2.70%. Svas Biosana SpA's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Svas Biosana SpA (MIL:SVS), the current FCF Margin % is 2.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Svas Biosana SpA (MIL:SVS) Overvalued in 2026?
Based on GuruFocus' analysis, Svas Biosana SpA stock appears to be undervalued.
The current stock price of €8.38 is trading 12.8% below its estimated GF Value™ of €9.61.
GuruFocus considers Svas Biosana SpA to be Modestly Undervalued.
Key valuation signals for MIL:SVS:
FCF Margin %: 2.70%
GF Value™: €9.61 vs. price of €8.38 (12.8% below fair value)
No single metric tells the full story. See the MIL:SVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:SVS has been successfully added to your 
